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The role of autoantibodies in primary biliary cirrhosis (PBC) is not only to aid in the diagnosis of this
disease but also to classify and assist in defining its prognosis. For the diagnosis of PBC, the patient
must have at least two of the following three parameters: clinical and/or biochemical characteristics
of cholestasis, reactivity of anti-mitochondrial antibodies, and histological changes associated with
cholestasis, particularly florid biliary lesions and portal granulomas.
There are two methods to detect AMAs. Indirect immunofluorescence (IIF) is the most common
method, using unfixed sections of the kidney and stomach from rodents as a substrate. The presence
of a fluorescent pattern in the cortical regions, and specifically in the medullary renal regions and
in the proximal, distal, and collecting tubules, is very characteristic of these antibodies (Figure 1A).
A concomitant staining in gastric parietal cells is usually observed. Alternatively, reactivity against
purified or recombinant antigens derived from the multi-enzyme 2-oxoacid dehydrogenase com-
plex (2-OADC) is observed, which consists of the pyruvate dehydrogenase complex, oxoglutarate
dehydrogenase complex, and branched-chain oxoacid dehydrogenase complex (particularly against
epitopes on their E2 subunits, which contain lipoic acid, a co-factor of these enzymes). With this
antigenic source, anti-2OADCantibodies can be detected using immunoblotting, immunodiffusion,
ELISA, and the Line immunoassay. Anti-M2 nomenclature for these antibodies should be avoided
because it uses an old classification of AMAs that has not yet been proven. A characteristic
cytoplasmic staining pattern observed by IIF when testing sera for antinuclear antibodies (ANAs)
called the “strand of beads” suggests the presence of AMAs (Figures 1B,C). Technical professionals
who perform the detection of autoantibodies and medical doctors who receive the results should
adequately examine the patient. The presence of this pattern needs to be confirmed using a specific
technique because it does not necessarily indicate AMA reactivity.
AMAs can be detected in over 90%of patients with PBC. In the vastmajority of patients (90–95%),
this reactivity is against the E2 subunit of the pyruvate dehydrogenase complex (74 kDa band by
immunoblotting). In addition, 50–80% of PBC patients react against the E2 subunit of the branched
chain oxoacid dehydrogenase complex (52 kDa) and 20–60% react against the E2 subunit of the
oxoglutarate dehydrogenase complex (48 kDa). Less frequently, the reactivity is against the E1a
(40 kDa) and E3 binding protein subunits (50 kDa) of the pyruvate dehydrogenase complex (1, 2).
Testing serum samples by ELISA or immunoblotting is important to confirm dubious fluorescent
patterns or negative sera by IIF. In this context, by investigating theAMAs by IIF and complementing
with ELISA and immunoblotting, the diagnosis can be confirmed in 95% of patients with clinical
and histological features of PBC. In our experience, immunoblotting is the best technique to study
anti-2OADC antibodies.
Although AMA reactivity is highly suggestive of PBC, the specificity of its presence for this
diagnosis is approximately 90%. AMA reactivity can be observed inAIH (5–10% of all AMA reactive
sera or 5% of patients with AIH) and characterizes a variant form of this disease without showing
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FIGURE 1 | (A) Typical fluorescent pattern of anti-mitochondrial antibodies reacting against the proximal, distal, and collecting tubules, leaving the glomeruli
unstained; (B) the cytoplasmic pattern ”strand of beads” and the nuclear envelope pattern; (C) multiple nuclear dot pattern.
other features of an overlapping syndrome. Its reactivity can also
be detected in some patients with chronic hepatitis C, as well as
in individual family members who are screened from a diagnosed
patient with PBC, and in patients tested for ANAs with rheumato-
logical diseases and normal values of alkaline phosphatase. Under
these conditions, a diagnosis of PBC cannot be defined without a
confirmatory liver biopsy (it is necessary to observe the presence
of at least two parameters as previously described). Even when a
liver biopsy is performed, the histological features of PBC are not
always present; thus, its diagnosis is not achieved. Nevertheless,
some patients will show features of the disease.
There are controversies if the AMA titers are related to disease
severity or disease progression. Dellavance et al. tested the sera
from four different groups with AMA reactivity, such as samples
obtained from patients with a definite diagnosis of PBC with or
without associated autoimmune diseases and from individuals
withAMAreactivity andnormal biochemical testswith orwithout
associated autoimmune diseases. Patientswho exhibited triple iso-
type AMA reactivity (IgG/IgM/IgA) by IIF, higher levels of anti-
pyruvate dehydrogenase complex by ELISA, higher anti-pyruvate
dehydrogenase avidity, and multiple antibody panel reactivity
had a more definite diagnosis of PBC with or without associated
autoimmune diseases. According to this study, the autoantibody
profile was quantitatively and qualitativelymore robust in patients
with a definite diagnosis of PBC (3). Evidence that the reactivity
of AMA has some relationship with the activity of the liver disease
is derived from the observation that patients in the early stage
of PBC treated with ursodeoxycholic acid can become AMA-
negative, but this event is uncommon (4). The strongest evidence
that favors a causal relationship between the pathogenesis of PBC
and AMA reactivity is derived from experimental models of PBC;
for example, one of the female SJLmice demonstrates a breakdown
in tolerance against PDC antigens with anti-PDC antibody pro-
duction followed by PBC-like biliary duct lesions, which is also
known as experimental autoimmune cholangitis (5). There are
other interesting models of the experimental induction of AMA
reactivity and the development of PBC-like biliary duct lesions
following the administration of xenobiotics in guinea-pigs and
mice (2, 6).
Antinuclear antibodies are frequently detected in PBC (in
approximately 50% of patients). Two patterns of ANAs are highly
specific: the nuclear envelope, the whose main target antigens of
which are gp210, p62, and the lamin B receptor, and multiple
nuclear dots, the main target antigens of which are sp100, sp140,
and promyelocytic leukemia protein (PML). Each of these pat-
terns can be observed in approximately 20–40% of patients
(Figures 1B,C). Anti-centromere antibodies tested positive in
10–30% of PBC patients and are frequently detected in patients
with a limited form of systemic scleroderma or Sjögren’s syn-
drome. In PBC patients without these diseases, their reactivity
could represent pre-clinical markers of these diseases (1).
In the vast majority of patients, the reactivity of ANAs is
present together with AMA reactivity. Nevertheless, close to 5%
of patients with clinical, biochemical, or histological features of
PBC have ANA reactivity detected alone and are classified as
AMA-negative PBC or autoimmune cholangitis. It is questionable
whether patients with AMA reactivity have different clinical man-
ifestations from those without AMA reactivity. However, itching
was less frequently observed in AMA-negative patients, and the
levels of alkaline phosphatase and IgM were lower in patients
with these serological features. By contrast, the bile duct damage
around the portal area wasmilder in AMA-reactive patients (6, 7).
Even in patients with both reactivity to AMA and ANA, there
is some evidence that those with ANA reactivity have a different
clinical behavior. As previously reported in several studies, the
persistence of reactivity of anti-gp210 is a strong risk factor for
the evolution to end-stage liver disease. Patients with anti-gp210
reactivity had more severe interface hepatitis, lobular inflamma-
tion, and ductular reactions. Moreover, the prognosis was more
favorable for patients who were initially positive for anti-gp210
and became negative during the course of therapy (1, 8–11).
Evidence suggesting that patients with reactivity for anti-
sp100 antibodies who have a more severe progressive disease
is less convincing than the evidence for anti-gp210. Interest-
ingly, the reactivity for these antibodies was more commonly
described in PBC patients who experienced a urinary tract infec-
tion (74 versus 4.8%) (12). In relationship to anti-centromere
antibodies, the results regarding this issue are inconclusive. How-
ever, some studies have suggested a relationship between anti-
centromere reactivity and the development of cirrhosis and portal
hypertension (1, 13).
In a study with Brazilian patients, AMAs and/or anti-
2OADC antibodies are disease markers close to 96%, and 4%
of patients have isolated reactivity against the nuclear envelope
and/or nuclear body proteins (the so-called AMA-negative PBC
or autoimmune cholangitis). Anti-centromere antibodies were
detected in 17.7% of all patients and in 32.4% of patients with
extra-hepatic autoimmune diseases, such as systemic scleroderma
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and/or Sjögren syndrome. Among the 130 patients who tested
positive for specific antibodies against nuclear antigens, 22.3 and
25.4% of patients demonstrated reactivity for nuclear envelope
proteins and multiple nuclear dots, respectively (3). These results
are very similar to those obtained at other centers (1, 2).
The overlap of PBC-specific antibodies is currently easier to
record due to the variety of commercially available ELISA assays.
In Liu’s study in 2010, 922 PBC patients with AMA reactivity by
IIF were tested using IgG/IgA dual isotype ELISA for detecting
multiple mitochondrial antibodies (against recombinant antigens
of the three enzymes of 2-OADC – MIT3) and nuclear autoan-
tibodies specific for PBC (anti-sp100 and anti-gp210) (14). In
patients with AMA-positive PBC, 92.4% were also positive for
anti-MIT3 and approximately 20% were positive for anti-gp210
and anti-sp100. Eight-hundred-sixty-eight (94.1%) patients were
positive using one or more specific ELISAs. However, the sera
of 16 (1.8%) patients demonstrated reactivity for only sp100 or
gp210 antigens. By contrast, in 253 patients with AMA-negative
PBC, 28.1 and 15% of patients were positive for anti-MIT3 and 15
were positive for anti-gp210 or anti-sp100, respectively. Further-
more, 117 (46.2%) patients were positive by one or more specific
ELISAs. However, 46 patients (39.3%) demonstrated reactivity
to only sp100 and/or gp210. The conclusion of this study was
that the detection of anti-MIT3 was valuable in AMA-negative
PBC by IIF.
Another method used to detect the overlap of PBC-related
antibodies is the line immunoassay. Using this technique, several
antigens are immobilized on strips and are incubated with serum
samples obtained from patients with suspected autoimmune
liver disease (15). In general, these commercial assays for the
simultaneous detection of several antibodies are expensive, and
the IIF technique continues to be the best method to initiate
the investigation of liver diseases because it simultaneously tests
several autoimmune liver disease-related autoantibodies.
In summary, the detection of autoantibodies for the diagno-
sis of PBC should follow this algorithm. Patients with chronic
cholestasis should be tested for AMAusing IIF. Patients with reac-
tivity are termed AMA-positive PBC patients, and patients with-
out chronic cholestasis should be tested against 2-OADC antigens
using immunoblotting or ELISA. Patients with any reactivity also
have AMA/anti-2OADC antibody-positive PBC. Patients without
reactivity to AMA and anti-2OADC antibodies should be tested
for specific ANAs, particularly against nuclear bodies and nuclear
envelope proteins by IIF or ELISA. Patients with any isolated
reactivity have AMA-negative PBC or autoimmune cholangitis.
Although PBC can be diagnosed without reactivity to AMA, anti-
2-OADC, or nuclear antigens according to international criteria,
we prefer to designate these patients as having non-PBC cholesta-
sis. Although there are controversies, the prognosis of liver disease
can be correlated to the ANA pattern.
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